---
title: "Lufax may delay the publication of its 2024 annual results and continue to suspend trading"
description: "Lufax announced that the independent investigation is expected to be completed by mid-April 2025, at which time the main investigation results and subsequent plans will be disclosed. The audit committ"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/230302237.md"
published_at: "2025-03-03T10:46:02.000Z"
---

# Lufax may delay the publication of its 2024 annual results and continue to suspend trading

> Lufax announced that the independent investigation is expected to be completed by mid-April 2025, at which time the main investigation results and subsequent plans will be disclosed. The audit committee is evaluating candidates for the successor auditor, who will cooperate to audit the financial reports for the years 2022 to 2024 after approval by the shareholders' meeting. Due to the time required for the audit, the annual performance for 2024 may be delayed in release, and the company's shares will continue to be suspended

According to the Zhitong Finance APP, LuKong (06623) announced that an independent investigation is still ongoing as of the date of this announcement. The independent investigation is currently expected to be substantially completed by mid-April 2025, after which the company will disclose the main investigation results and any further actions (if any) regarding the mentioned transactions.

As of the date of this announcement, the audit committee is evaluating candidates for the company's successor auditor. After shareholders approve the proposed appointment at the shareholders' meeting, the company will cooperate with the successor auditor based on their opinions and acceptance procedures to audit the company's financial reports for the years ending December 31, 2022, 2023, and 2024. The company will make a separate announcement after selecting the successor auditor.

Due to the time required for the successor auditor to complete the audit work, it may lead to a delay in the company's publication of the 2024 annual results.

In addition, the company's shares remain suspended

### Related Stocks

- [LU.US - Lufax](https://longbridge.com/en/quote/LU.US.md)
- [06623.HK - LUFAX](https://longbridge.com/en/quote/06623.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Rosen Law Firm Encourages Lufax Holding Ltd Investors to Inquire About Securities Class Action Investigation – LU | Rosen Law Firm is investigating potential securities claims for shareholders of Lufax Holding Ltd (NYSE: LU) due to alle | [Link](https://longbridge.com/en/news/276295283.md) |
| Intellego Technologies Received Independent Forensic Review From KPMG | Intellego Technologies AB :SAID ON THURSDAY HAS RECEIVED INDEPENDENT FORENSIC REVIEW FROM KPMG OF THE PARENT COMPANY’S F | [Link](https://longbridge.com/en/news/276421782.md) |
| Gold Fields Limited Announces Final Dividend for Year Ended 31 December 2025, Payable on 16 March 2026 | Gold Fields Limited announced a final dividend for year ended 31 December 2025, number 103 of 1850 SA cents per share (g | [Link](https://longbridge.com/en/news/276467029.md) |
| Tenaris Reports Lower 2025 Revenue but Sustains Strong Profitability in Latest SEC Filing | Tenaris S.A. reported a decline in revenue for 2025, with net sales of $11.98 billion, down from $12.52 billion in 2024  | [Link](https://longbridge.com/en/news/276437126.md) |
| Ocular Therapeutix Director Pravin Dugel Sells Shares | Pravin Dugel, Director at Ocular Therapeutix, sold 124,882 shares of Common Stock on February 12, 2026, at an average pr | [Link](https://longbridge.com/en/news/276188254.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.